

Client: ARUP Example Report Only
500 Chipeta Way
Salt Lake City, UT 84108
UNITED STATES

Physician: ARUP, ARUP

Patient: Neg, SMADDFE

DOB

Sex: Female

Patient Identifiers: 46722

Visit Number (FIN): 47058

Collection Date: 2/22/2023 08:44

Spinal Muscular Atrophy (SMA) Copy Number Analysis, Fetal

ARUP test code 2013444

| | | |
|---|----------------|---|
| Maternal Contamination Study Fetal Spec | Fetal Cells | Single fetal genotype present; no maternal cells present. Fetal and maternal samples were tested using STR markers to rule out maternal cell contamination. |
| Maternal Contam Study, Maternal Spec | whole Blood | |
| SMA Copy Number, Specimen | Cultured Amnio | |
| SMA Copy Number, SMN1 Copies | 2 copies | |
| SMA Copy Number, SMN2 Copies | 2 copies | |
| SMA Copy Number, Interp | See Note | <p>Indication for testing: Prenatal diagnosis.</p> <p>Result: SMN1 gene copies: 2 copies SMN2 gene copies: 2 copies</p> <p>Interpretation: Two copies of the SMN1 gene were detected by multiplex ligation-dependent probe amplification (MLPA) in this prenatal sample. This result significantly reduces the likelihood that this fetus is affected with spinal muscular atrophy (SMA). Please refer to the background information included in this report for the clinical sensitivity and limitations of this test.</p> <p>Recommendations: Genetic consultation is recommended.</p> <p>BACKGROUND INFORMATION: Spinal Muscular Atrophy (SMA) Copy Number Analysis, Fetal CHARACTERISTICS: Spinal muscular atrophy (SMA) is the most common lethal genetic disease in children. It is characterized by progressive muscle atrophy and weakness, poor weight gain, restrictive lung disease, scoliosis, and joint contractures due to degeneration of lower motor neurons and brain stem nuclei. Onset ranges from before birth to young adulthood and severity is highly variable. Individuals with SMA have no functional copies of the SMN1 gene either due to homozygous loss of SMN1 from deletion or gene conversion (95 percent) or loss of one SMN1 gene and a pathogenic sequence variant in the other (5 percent). The SMN2 gene produces a small amount of functional</p> |

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Neg, SMADDFE
ARUP Accession: 23-053-101299
Patient Identifiers: 46722
Visit Number (FIN): 47058
Page 1 of 2 | Printed: 2/22/2023 11:19:15 AM

survival motor neuron protein compared to SMN1. An increased number of SMN2 gene copies may reduce disease severity but phenotype cannot be predicted with certainty.
INHERITANCE: Autosomal recessive.
CAUSE: Pathogenic variants in the SMN1 gene.
VARIANTS TESTED: For copy number: SMN1 (NM_000344.3) exon 7 c.840C and exon 8 c.*239G, and SMN2 (NM_017411.3) exon 7 c.840T.
CLINICAL SENSITIVITY: 95-98 percent.
METHODOLOGY: Multiplex probe ligation-dependent amplification (MLPA).
ANALYTICAL SENSITIVITY AND SPECIFICITY: 99 percent.
LIMITATIONS: Diagnostic errors can occur due to rare sequence variations. Single base pair substitutions, small deletions/duplications, regulatory region and deep intronic variants will not be detected. This test is unable to determine chromosomal phase of SMN1 or SMN2 copies.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

VERIFIED/REPORTED DATES

| Procedure | Accession | Collected | Received | Verified/Reported |
|---|---------------|----------------------|----------------------|-----------------------|
| Maternal Contamination Study Fetal Spec | 23-053-101299 | 2/22/2023 8:44:00 AM | 2/22/2023 8:45:21 AM | 2/22/2023 11:13:00 AM |
| Maternal Contam Study, Maternal Spec | 23-053-101299 | 2/22/2023 8:44:00 AM | 2/22/2023 8:45:21 AM | 2/22/2023 11:13:00 AM |
| SMA Copy Number, Specimen | 23-053-101299 | 2/22/2023 8:44:00 AM | 2/22/2023 8:45:21 AM | 2/22/2023 11:13:00 AM |
| SMA Copy Number, SMN1 Copies | 23-053-101299 | 2/22/2023 8:44:00 AM | 2/22/2023 8:45:21 AM | 2/22/2023 11:13:00 AM |
| SMA Copy Number, SMN2 Copies | 23-053-101299 | 2/22/2023 8:44:00 AM | 2/22/2023 8:45:21 AM | 2/22/2023 11:13:00 AM |
| SMA Copy Number, Interp | 23-053-101299 | 2/22/2023 8:44:00 AM | 2/22/2023 8:45:21 AM | 2/22/2023 11:13:00 AM |

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Neg, SMADDFE
ARUP Accession: 23-053-101299
Patient Identifiers: 46722
Visit Number (FIN): 47058
Page 2 of 2 | Printed: 2/22/2023 11:19:15 AM